Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, argenx SE's Enterprise Value is €51,911 Mil.
argenx SE's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €0 Mil. Therefore, argenx SE's EV-to-OCF for today is .
The historical rank and industry rank for argenx SE's EV-to-OCF or its related term are showing as below:
FRA:1AE'
s EV-to-OCF Range Over the Past 10 Years
Min: 88.71 Med: 0 Max: 88.71
Current: 88.71
During the past 13 years, the highest EV-to-OCF of argenx SE was 88.71. The lowest was 88.71. And the median was .
FRA:1AE's EV-to-OCF is ranked worse than 97.08% of 1406
companies
in the Biotechnology industry
Industry Median: -3.69
vs FRA:1AE: 88.71
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
argenx SE's share price for today is €883.60.
argenx SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €22.564.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
argenx SE EV-to-OCF Related Terms
argenx SE EV-to-OCF Historical Data
* Premium members only.
The historical data trend for argenx SE's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, argenx SE's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where argenx SE's EV-to-OCF falls into.
argenx SE's current Enterprise Value is €51,911 Mil.
argenx SE's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is argenx SE (FRA:1AE) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of €883.60 is trading 30.2% below its estimated GF Value™ of €1,265.97.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for FRA:1AE:
EV-to-OCF:
GF Value™: €1,265.97 vs. price of €883.60 (30.2% below fair value)
No single metric tells the full story. See the FRA:1AE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score
Get the complete analysis for FRA:1AE
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1AE has been successfully added to your 
